DOCSLIB.ORG

Neurological Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neurological Disease Neurological Disease A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, strokelike episodes and dementia and depend on the part of the nervous system affected. www.MedChemExpress.com 1 Neurological Disease Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (+)-Dihydrexidine hydrochloride Cat. No.: HY-76772A (DAR-0100 hydrochloride) Cat. No.: HY-101299 Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: (+)-Dihydrexidine hydrochloride is a dopamine D1 receptor receptor agonist, is a candidate therapeutic drug for agonist with an EC50 of 72± 21 nM. xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 250 mg, 500 mg 1 mg, 5 mg (+)-MK 801 Maleate (+)-PD 128907 hydrochloride (Dizocilpine maleate; Dizocilpine hydrogen maleate) Cat. No.: HY-15084 Cat. No.: HY-110000 Bioactivity: (+)-MK 801 Maleate is a potent, selective and non-competitive Bioactivity: (+)-PD 128907 hydrochloride is a selective dopamine D2/D3 NMDA receptor antagonist with Kd of 37.2 nM in rat brain receptor agonist, with Kis of 1.7, 0.84 nM for human and rat D membranes. 3 receptors, 179, 770 n M for human and rat D 3 receptors, respectively. Purity: 99.98% Purity: 98.83% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 10 mg, 50 mg 5 mg, 10 mg, 25 mg, 50 mg (+)-PHENSERINE (-)-(S)-Equol Cat. No.: HY-16009 Cat. No.: HY-100583 Bioactivity: Posiphen is a novel selective cholinesterase noncompetitive Bioactivity: (-)-(S)-Equol is a high affinity ligand for estrogen receptor inhibitor with an IC50 of 45.3 μM. β with a Ki of 0.73 nM. Purity: >98% Purity: 99.82% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 250 mg, 500 mg Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg (-)-Aspartic acid (-)-Borneol ((R)-Aspartic acid; D-(-)-Aspartic acid) Cat. No.: HY-42068 (L-Borneol) Cat. No.: HY-N1368B Bioactivity: (-)-Aspartic acid is an endogenous NMDA receptor agonist. Bioactivity: (-)-Borneol has a highly efficacious positive modulating action at GABA receptor with an EC50 of 237 μM. Purity: 97.0% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 g 100 mg (-)-Cevimeline hydrochloride hemihydrate (-)-Huperzine A Cat. No.: HY-76772B (Huperzine A) Cat. No.: HY-17387 Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Huperzine A, an active Lycopodium alkaloid extracted from receptor agonist, is a candidate therapeutic drug for traditional Chinese herb, is a potent, selective and xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR reversible acetylcholinesterase (AChE) inhibitor and has been The general pharmacol. properties of this drug on the widely used in China for the treatment of Alzheimer's disease gastrointestinal, urinary, and reproductive systems and other… (AD). Purity: >98% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 5 mg, 10 mg 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] (-)-MK 801 Maleate (-)-Securinine Cat. No.: HY-15084A Cat. No.: HY-N2079 Bioactivity: (-)-MK 801 Maleate is the enantiomer of (+)-MK-801. (+)-MK 801 Bioactivity: (-)-Securinine is plant-derived alkaloid and also a GABAA Maleate is a potent, selective and non-competitive NMDA receptor antagonist. receptor antagonist. Purity: 99.70% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 10 mg, 50 mg 5 mg, 10 mg, 25 mg (1R,2R)-2-PCCA(hydrochloride) (1R,2S)-VU0155041 Cat. No.: HY-100013A1 Cat. No.: HY-14417A Bioactivity: (1R,2R)-2-PCCA hydrochloride is a diastereomer of 2-PCCA, and Bioactivity: (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is a partial acts as a potent GPR88 receptor agonist, with an EC50 of 3 mGluR4 agonist with an EC50 of 2.35 μM. nM. Purity: 98.08% Purity: 98.42% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg 5 mg, 10 mg, 25 mg (Arg)9 (R)-(-)-Rolipram (Nona-L-arginine; Peptide R9) Cat. No.: HY-P0133 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A Bioactivity: (Arg)9 (Nona-L-arginine;Peptide R9) is a cell-penetrating Bioactivity: (R)-(-)-Rolipram is the R-enantiomer of Rolipram. Rolipram is peptide; exhibits neuroprotective activity with an IC50 of a selective inhibitor of phosphodiesterases PDE4 with IC50 of 0.78 μM in the glutamic acid model. Sequence: 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg. respectively. Purity: >98% Purity: 99.85% Clinical Data: Phase 2 Clinical Data: Phase 1 Size: 1 mg, 5 mg Size: 10mM x 1mL in DMSO, 10 mg, 50 mg (R)-5-Hydroxymethyl Tolterodine (R)-ADX-47273 (Desfesoterodine; PNU-200577) Cat. No.: HY-76569 Cat. No.: HY-13058B Bioactivity: (R)-5-Hydroxymethyl Tolterodine(PNU-200577; Desfesoterodine) Bioactivity: (R)-ADX-47273 is a potent mGluR5 positive allosteric is a potent and selective muscarinic receptor antagonist with modulator, with an EC50 of 168 nM for potentiation . a Kb and a pA2 of 0.84 nM and 9.14, respectively. Purity: 99.66% Purity: 99.25% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg 5 mg, 10 mg, 50 mg (R)-Baclofen (R)-Baclofen hydrochloride (STX209) Cat. No.: HY-17354 (STX 209 hydrochloride) Cat. No.: HY-17354A Bioactivity: (R)-Baclofen(STX209) is a selective GABAB receptor agonist. Bioactivity: (R)-Baclofen Hcl(STX-209 Hcl) is a derivative of IC50 value: Target: GABAB receptor GABAB receptors are gamma-aminobutyric acid (GABA) primarily used to treat metabotropic receptors which produce slow inhibitory signals. spasticity and is in the early research stages for use for the By manipulating GABAB receptor activity using Baclofen, a treatment of alcoholism. Target: GABA Baclofen (brand names variety of functions are studied including synaptic… Kemstro, Lioresal, Liofen, Gablofen, Beklo and Baclosan) is a… Purity: 98.0% Purity: >98% Clinical Data: Phase 3 Clinical Data: Phase 3 Size: 10mM x 1mL in Water, Size: 10 mg, 50 mg 10 mg, 50 mg www.MedChemExpress.com 3 (R)-Oxiracetam (RS)-MCPG ((R)-(+)-Oxiracetam) Cat. No.: HY-17554 (alpha-MCPG) Cat. No.: HY-100371 Bioactivity: (R)-Oxiracetam is the (R)-enantiomer of the nootropic drug Bioactivity: (RS)-MCPG is a non-selective group I/group II metabotropic oxiracetam. Oxiracetam (ISF 2522) is a nootropic drug of the glutamate receptor antagonist. racetam family and stimulant. Purity: >98% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg 5 mg, 10 mg, 25 mg, 50 mg, 100 mg (S)-(-)-5-Fluorowillardiine (S)-(-)-5-Fluorowillardiine hydrochloride ((5S)-Fluorowillardiine; (S)-5-Fluorowillardiine) Cat. No.: HY-16713 ((5S)-Fluorowillardiine hydrochloride; …) Cat. No.: HY-16713A Bioactivity: (S)-(-)-5-Fluorowillardiine is a potent and specific AMPAR Bioactivity: (S)-(-)-5-Fluorowillardiine Hcl is a potent and specific AMPAR agonist. agonist. Purity: >98% Purity: 99.82% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mg, 50 mg Size: 10mM x 1mL in DMSO, 10 mg, 50 mg (S)-Glutamic acid (S)-MCPG ((+)-L-Glutamic acid) Cat. No.: HY-14608 ((+)-MCPG) Cat. No.: HY-100406 Bioactivity: (S)-Glutamic acid acts as an excitatory transmitter, shows a Bioactivity: (S)-MCPG is the active isomer of (RS)-MCPG (Cat. No. direct activating effect on the release of DA from HY-100371), non-selective group I/group II metabotropic dopaminergic terminals. glutamate receptor antagonist. In vivo: (S)-MCPG (20.8 μg) injected intraventricularly (i.c.v.) before testing impaired the performance of rats in the spatial version of the Morris… Purity: >98% Purity: 98.10% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 100 mg, 500 mg 5 mg, 10 mg, 25 mg, 50 mg (S)-Timolol Maleate (S)-Willardiine (Timolol Maleate) Cat. No.: HY-17380 ((-)-Willardiine) Cat. No.: HY-12499 Bioactivity: (S)-Timolol maleate, is a potent non-selective β-adrenergic Bioactivity: (S)-Willardiine is a potent agonist of AMPA/kainate receptors receptor antagonist (Ki values are 1.97 and 2.0 nM for β1 and with EC50 of 44.8 uM. IC50 value: 44.8 uM(EC50) [1] Target: β2 receptor subtypes respectively). IC50 Value: 1.97 nM(Ki for AMPA/kainate receptor agonist in vitro: The (S)- but not β1); 2.0 nM(Ki for β2) Target: β-adrenergic receptor (R)-isomers of willardiine and 5-bromowillardiine were potent (S)-Timolol, 50% bioavailability following oral… agonists, producing rapidly but incompletely desensitizing… Purity: 99.87% Purity: 98.70% Clinical Data: Launched Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 100 mg, 200 mg 10 mg, 50 mg (Z)-Hexadec-9-enoic acid (Z)-Thiothixene Cat.
Load more

Recommended publications
  • Optumrx Brand Pipeline Forecast
    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
    [Show full text]
  • E30 SEM. O.C. Disclosed Is a Compound Represented by the Formula (1) (51) Int
    USOO9453000B2 (12) United States Patent (10) Patent No.: US 9.453,000 B2 Kimura et al. (45) Date of Patent: *Sep. 27, 2016 (54) POLYCYCLIC COMPOUND (56) References Cited (75) Inventors: Teiji Kimura, Tsukuba (JP); Noritaka U.S. PATENT DOCUMENTS Kitazawa, Tsukuba (JP); Toshihiko 3,470,167 A 9, 1969 Sarkar Kaneko, Tsukuba (JP); Nobuaki Sato, 3,989,816 A 1 1/1976 Rajadhyaksha Tsukuba (JP); Koki Kawano, Tsukuba 4,910,200 A 3, 1990 Curtze et al. (JP): Koichi Ito, Tsukuba (JP); 5,281,626 A 1/1994 Oinuma et al. M s Tak ishi Tsukub JP 5,563,162 A 10, 1996 Oku et al. amoru Takaishi Tsukuba (JP); 5,804,577 A 9, 1998 Hebeisen et al. Takeo Sasaki, Tsukuba (JP); Yu 5,985,856 A 11/1999 Stella et al. Yoshida, Tsukuba (JP); Toshiyuki 6,235,728 B1 5, 2001 Golik et al. Uemura, Tsukuba (JP); Takashi Doko, g R 1939. E. al. Its SE E. Shinmyo, 7,138.414 B2 11/2006 Schoenafingereatch et al. et al. sukuba (JP); Daiju Hasegawa, 7,300,936 B2 11/2007 Parker et al. Tsukuba (JP); Takehiko Miyagawa, 7,314,940 B2 1/2008 Graczyk et al. Hatfield (GB); Hiroaki Hagiwara, 7,618,960 B2 11/2009 Kimura et al. Tsukuba (JP) 7,667,041 B2 2/2010 Kimura et al. 7,687,640 B2 3/2010 Kimura et al. 7,713,993 B2 5/2010 Kimura et al. (73) Assignee: EISAI R&D MANAGEMENT CO., 7,737,141 B2 6/2010 Kimura et al. LTD., Tokyo (JP) 7,880,009 B2 2/2011 Kimura et al.
    [Show full text]
  • Safety and Tolerability of Arimoclomol in Patients with Sporadic Inclusion Body Myositis: a Randomised, Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial
    Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept trial Sporadic inclusion body myositis (IBM) is the commonest idiopathic inflammatory myopathy (IIM) occurring in patients over the age of 50 years.1-4 The prevalence of IBM differs between different populations and ethnic groups, with estimates between 4.9-70.6 per million population.5-10 IBM is distinguished from the other IIM by early asymmetric finger flexor and knee extensor weakness (leading to loss of hand function and propensity to fall) and resistance to immunosuppressive therapy. Any skeletal muscle can be affected, including oesophageal and pharyngeal muscles. Late-stage disease can be characterized by very significant morbidity including disability and loss of quality of life. Death in IBM is related to malnutrition, cachexia, aspiration, respiratory infection and respiratory failure, as a consequence of dysphagia, severe global weakness and weakness of the respiratory muscles.1-4 In a Dutch cohort, end-of-life care interventions were used by 13% of patients with IBM, highlighting the morbidity experienced by these patients and the need of supportive and palliative care in this disease.2 The aetiopathogenesis of IBM remains uncertain. The varied pathological findings observed have driven a number of theories including viral infection, accumulation of toxic proteins, autoimmune attack, myonuclear degeneration, endoplasmic reticulum stress and impairment of autophagy and proteasomal proteolysis.11-15 Muscle biopsies from patients with IBM typically show several different pathological features broadly described as inflammatory or degenerative. Inflammatory features include endomysial infiltration by mononuclear cells (predominantly CD8+ T- cells), which surround and invade otherwise normal appearing muscle fibres, and overexpression of major histocompatibility complex (MHC) class I, which is not constitutively expressed by skeletal muscle.
    [Show full text]
  • Beyond Monoamines Towards the Development of Novel Antidepressants Oltre Le Monoamine Al Fine Di Sviluppare Nuovi Farmaci Antidepressivi
    Original article • Articolo originale Beyond monoamines towards the development of novel antidepressants Oltre le monoamine al fine di sviluppare nuovi farmaci antidepressivi M. Fornaro1,2 1 Department of “Scienze della Formazione”, University of Catania, Italy; 2 Department of Psychiatry, Veteran Affairs (VA) Hospital, University of California (UCSD), La Hoya, San Diego, CA, USA Summary ated giving priority to RCTs and meta-analyses. At present, the pharmacological management of depression appears is Objective characterized by a wide variety of different augmentation or Herein, a concise review is presented on the current and most switching approaches (Fig. 1). Nonetheless, response rates promising antidepressant pharmacological agents for manage- remain substantially unsatisfactory, thus prompting for the ment of depression. development of novel agents with different mechanisms of action. Materials and methods A PubMed search (1966 - February 2012) was performed using Conclusions the following keywords or their combination: “depression”; Shifting the interest for novel antidepressant drugs beyond the “major depressive disorder”: “antidepressants”; “novel antide- monoaminergic modulation represents (Tables I-III) an intriguing pressant targets”; “monoamine”; “novel antidepressants”. Ad- opportunity to enhance response rates of depression, although ditional literature sources, including most authoritative and up- other issues, including revision of current nosological bounda- dated edited books or pamphlets were examined accordingly.
    [Show full text]
  • Effects of Chronic Systemic Low-Impact Ampakine Treatment On
    Biomedicine & Pharmacotherapy 105 (2018) 540–544 Contents lists available at ScienceDirect Biomedicine & Pharmacotherapy journal homepage: www.elsevier.com/locate/biopha Effects of chronic systemic low-impact ampakine treatment on neurotrophin T expression in rat brain ⁎ Daniel P. Radin , Steven Johnson, Richard Purcell, Arnold S. Lippa RespireRx Pharmaceuticals, Inc., 126 Valley Road, Glen Rock, NJ, 07452, United States ARTICLE INFO ABSTRACT Keywords: Neurotrophin dysregulation has been implicated in a large number of neurodegenerative and neuropsychiatric Ampakine diseases. Unfortunately, neurotrophins cannot cross the blood brain barrier thus, novel means of up regulating BDNF their expression are greatly needed. It has been demonstrated previously that neurotrophins are up regulated in Cognitive enhancement response to increases in brain activity. Therefore, molecules that act as cognitive enhancers may provide a LTP clinical means of up regulating neurotrophin expression. Ampakines are a class of molecules that act as positive Neurotrophin allosteric modulators of AMPA-type glutamate receptors. Currently, they are being developed to prevent opioid- NGF induced respiratory depression without sacrificing the analgesic properties of the opioids. In addition, these molecules increase neuronal activity and have been shown to restore age-related deficits in LTP in aged rats. In the current study, we examined whether two different ampakines could increase levels of BDNF and NGF at doses that are active in behavioral measures of cognition. Results demonstrate that ampakines CX516 and CX691 induce differential increases in neurotrophins across several brain regions. Notable increases in NGF were ob- served in the dentate gyrus and piriform cortex while notable BDNF increases were observed in basolateral and lateral nuclei of the amygdala.
    [Show full text]
  • Analysis of Metals in Surface Water Samples
    ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Annex I Analysis of metals in surface water samples Environmental Institute, s.r.o., Okružná 784/42, 972 41 Koš, Slovakia October 2020 EUWI+, Investigative monitoring of the Dnieper River Basin, October 2020 ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Surface water samples Cd (ug/L) Pb (ug/L) Hg (ug/L) Ni (ug/L) As (ug/L) Cr (ug/L) Cu (ug/L) Zn (ug/L) Metals – limit values 0.15** 1.2** 0.07*** 4** 24* 9.0* 1.6* 9.6* Table 1: Results of analyses of Sampling point 1 filtered <LOQ <LOQ <LOQ <LOQ 3.38 <LOQ 1.15 4.0 metals in surface water samples. Sampling point 2 filtered 0.547 <LOQ <LOQ 1.845 <LOQ 0.666 1.94 26.5 The values represent dissolved Sampling point 3 filtered <LOQ <LOQ <LOQ <LOQ 1.99 <LOQ 0.89 4.1 concentrations (after filtration of Sampling point 4 filtered <LOQ <LOQ <LOQ 1.33 <LOQ <LOQ 4.21 9.2 the samples). Numbers Sampling point 5 filtered 2.66 <LOQ <LOQ <LOQ <LOQ 2.35 9.39 20.6 highlighted in orange colour Sampling point 6 filtered <LOQ <LOQ <LOQ <LOQ 2.62 <LOQ 4.95 6.9 indicate exceedance of the Sampling point 7 filtered 0.345 <LOQ <LOQ <LOQ <LOQ 0.777 6.06 38.4 toxicity threshold values. Sampling point 8 filtered <LOQ <LOQ <LOQ <LOQ 2.65 <LOQ 1.03 61.7 Sampling point 9 filtered 0.129 <LOQ <LOQ <LOQ 2.29 0.85 5.36 16.4 Sampling point 10 filtered <LOQ <LOQ <LOQ 1.772 <LOQ <LOQ <LOQ 7.9 Sampling point 11 filtered 0.292 <LOQ <LOQ <LOQ <LOQ 1.31 0.82 11.9 Sampling point 12 filtered 0.328 <LOQ <LOQ <LOQ <LOQ 3.89 1.34 2.6 Sampling point 13 filtered <LOQ
    [Show full text]
  • 42711 IPEG Programmaboekje
    19 th Biennial Conference 19th Biennial Conference October 26th – 30th 2016 October 26 Nijmegen, the Netherlands th – 30 th 2016 Nijmegen, the Netherlands 2016 Nijmegen, 42711 IPEG programmaboekje omslag.indd 1 06-10-16 17:52 The “International Pharmaco-EEG Society, Association for Electrophysiological Brain Research in Preclinical and Clinical Pharmacology and Related Fields” (IPEG) is a non-profit organization, established in 1980 and composed of scientists and researchers actively involved in electrophysiological brain research in preclinical and clinical pharmacology, neurotoxicology and related areas of interest. my.thesis nl for the design of your Thesis & to show your Thesis 42711 IPEG programmaboekje omslag.indd 2 06-10-16 17:52 IPEG 2016 in Nijmegen | 1 Welcome to Nijmegen, dear attendants of the 19th IPEG meeting. Nijmegen, a 2000 year old city; Nijmegen, a Roman and a medieval city; Nijmegen, the home town of the first catholic university funded by the Faithfull to improve education of a suppressed part of the Netherlands; Nijmegen, the city that heavily suffered in WWII; Nijmegen, the home town of the Donders Institute. Nijmegen, as we hope and trust, your home town for the upcoming IPEG meeting. As you all know, electrophysiological brain research has a long tradition going back as far as 1875 when the first report on the animal electroencephalogram (EEG) was published by Caton. The often forgotten Polish physiologist Adolf Beck was also a EEG pioneer many years before Hans Berger’s initial reports. Beck recorded electrical potentials in several brain areas evoked by peripheral sensory stimuli. Using this technique, Beck localised various centres in the brain of several animal species and described desynchronization in electrical brain potentials.
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • 19Th Biennial IPEG Meeting Nijmegen, the Netherlands
    Neuropsychiatric Electrophysiology 2016, 2(Suppl 1):8 DOI 10.1186/s40810-016-0021-4 MEETINGABSTRACTS Open Access 19th biennial IPEG Meeting Nijmegen, The Netherlands. 26-30 October 2016 Published: 29 November 2016 Training course measures. This will be illustrated by means of pertinent examples. These include elucidating the mechanisms of stimulant action re- A1 mediating deficient impulse control and the role of the cannabinoid Thalamocortical sleep oscillations system in human working memory, as well as drug effects on Igor Timofeev1,2 sensory gating and specific aspects of visual-spatial attention. Other 1Department of Psychiatry and Neuroscience, Université Laval, Québec, examples concern the added sensitivity of EEG and ERP measures, Canada; 2Centre de recherche de l’Institut universitaire en santé mentale relative to that of performance measures, in detecting effects of alco- de Québec (CRIUSMQ), Université Laval, Québec, Canada hol, and more generally in monitoring and predicting vigilance and Neuropsychiatric Electrophysiology 2016, 2(Suppl 1):A1 the ability to detect external signals in the immediate future. Rela- tions between brain signals and cognitive competences are revealed In waking and sleeping states, thalamocortical system generates a by either comparing different individuals, or moment-to-moment variety of oscillations ranging from 0.1 Hz to hundreds of Hz. Most of fluctuations within individuals, or differences in state (e.g., drug- them are present during NREM sleep, but slower activities prevail in induced) within individuals. this state of vigilance. Thalamocortical network is organized in a loop in which thalamocortical cells excite reticular thalamic and neocor- tical cells, reticular thalamic cells inhibit thalamocortical cells and A3 corticothalamic cells excite thalamocortical and reticular thalamic EEG and ERP as key techniques for functional brain alterations cells.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Integrating Treatment for Autism Spectrum Disorders Through the Life Cycle
    Integrating Treatment for Autism Spectrum Disorders Through the Life Cycle Robert L Hendren, DO Professor of Psychiatry and Behavioral Science Idaho Autism Summit November 2, 2019 Faculty Disclosure • Grants — Curemark, Roche, Otsuka • Advisory Board — Curemark, BioMarin, Janssen, Axial Biotherapeutics • Honoraria/Royalties: Oxford University Press, Taylor & Francis • Dr. Hendren does intend to discuss the use of off- label/unapproved use of drugs Learning Objectives • Identify successes and challenges in the developmental progression through the life cycle for people with developmental disabilities and their families • Identify and effectively treat comorbid medical, emotional and behavioral symptoms associated with autism spectrum disorders (ASD) • Consider integrating biomedical treatments for ASD including conventional psychotropic medication and what has been referred to as CAM/CIM into a comprehensive program. 2010 1 in 68; 2014 1 in 59 CDC Prevalence of Autism • Possible explanations include – Diagnostic expansion and substitution – Better reporting – Increased recognition – Increasing acceptability – Immigration for services – Environmental toxins – Infectious and immune vulnerability – Epigenetic processes Rutter M. Acta Pediatr. 2005;94(1):2-15. Centers for Disease Control and Prevention. Autism Spectrum Disorders. www.cdc.gov/ncbddd/autism. Accessed June 16, 2015. Hagerman R, Hendren RL (Eds). Treatment of Neurodevelopmental Disorders: Targeting Neurobiological Mechanisms. Oxford University Press; 2014. ASD Genetic Etiology (Levels 1 & 2) • Multiple genes: NRXN12q, 7q11.23, 15q11-13, 16p11.2, SHANK 3, 2, NLGN4, MTHFR 677>T, SEMA5A, 2Q22.1, GRIN2B, 5P14.1, CDH9, 10, FRX, PTEN • Identical twins: 60% to 90% – Fraternal twins: 0% to 36% – Siblings: 4% to 19% • Clear genetic etiology accounts for 25% of autism cases • Hundreds of genetic mutations, some de novo, lead to many ways to develop and treat autism • Is Precision Medicine Possible? Weiss KM, Issues Science and Technology in 2017 Levy D, et al.
    [Show full text]